[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100403102":3},{"organization":4,"armGroups":7,"interventions":25,"overallOfficials":31,"centralContacts":31,"locations":45,"responsibleParty":58,"collaborators":62,"id":69,"slug":70,"hasResults":71,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":71,"sex":77,"minAge":78,"maxAge":79,"enrollmentInfo":80,"targetDuration":31,"studyType":83,"phases":84,"briefSummary":86,"conditions":87,"keywords":31,"overallStatus":90,"whyStopped":91,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},{"fullName":5,"class":6},"Abderrahmane Mami Hospital","OTHER",[8,15,20],{"label":9,"type":10,"description":11,"interventionNames":12},"HCQ+Azithromycin","EXPERIMENTAL","* Hydroxychloroquine (HCQ): 600 mg on the 1st day as a starting dose then 200 mg \\* 2 \u002F D for 9 days\n* Azithromycin: 500 mg (1st day) then 250 mg \u002F D for 4 days\n* Usual standard treatment",[13,14],"Drug: HCQ","Drug: Azithromycin",{"label":16,"type":10,"description":17,"interventionNames":18},"HCQ+Azithromycin+Zinc","* HCQ: 600 mg on the 1st day as a starting dose then 200 mg \\* 2 \u002F D for 9 days\n* Azithromycin: 500 mg (1st day) then 250 mg \u002F D for 4 days\n* Zinc: 220 mg per day for 10 days\n* Usual standard treatment",[13,14,19],"Dietary Supplement: Zinc",{"label":21,"type":10,"description":22,"interventionNames":23},"Azithromycin+Doxycycline","* Azithromycin: 500 mg (1st day) then 250 mg \u002F D for 4 days\n* Doxycycline: 200 mg per day for 10 days.\n* Usual standard treatment",[14,24],"Drug: Doxycycline",[26,32,36,40],{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"DRUG","HCQ","600 mg on the 1st day as a starting dose then 200 mg \\* 2 \u002FD for 9 days",[9,16],null,{"type":27,"name":33,"description":34,"armGroupLabels":35,"otherNames":31},"Azithromycin","500 mg (1st day) then 250 mg \u002F D for 4 days",[21,9,16],{"type":27,"name":37,"description":38,"armGroupLabels":39,"otherNames":31},"Doxycycline","200 mg per day for 10 days",[21],{"type":41,"name":42,"description":43,"armGroupLabels":44,"otherNames":31},"DIETARY_SUPPLEMENT","Zinc","220 mg per day for 10 days",[16],[46],{"facility":47,"status":31,"city":48,"state":31,"zip":49,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":31},"Eshmoun Clinical Research Centre","Tunis","1053","Tunisia","TN",{"type":53,"coordinates":54},"Point",[55,56],10.16579,36.81897,{"lat":56,"lon":55},{"type":59,"investigatorFullName":60,"investigatorTitle":61,"investigatorAffiliation":5,"oldNameTitle":31,"oldOrganization":31},"PRINCIPAL_INVESTIGATOR","Dr Jalila Ben Khelil","Head of department",[63,66],{"name":64,"class":65},"Eshmoun Clinical Research Center","NETWORK",{"name":67,"class":68},"Datametrix","INDUSTRY","100403102","phase-3-evaluation-of-the-efficacy-and-safety-of-treatments-for-patients-hospitalized-for-covid-19-infection-without-signs-of-acute-respiratory-failure-in-tunisia-100403102",false,"NCT04528927","Evaluation of the Efficacy and Safety of Treatments for Patients Hospitalized for COVID-19 Infection Without Signs of Acute Respiratory Failure, in Tunisia","Evaluation of the Efficacy and Safety of Treatments for Patients Hospitalized for COVID-19 Infection Without Signs of Acute Respiratory Failure, in Tunisia Multicentric Randomized Comparative Study","THINC","Inclusion Criteria:\n\n* Confirmed patient COVID19 positive with clinical signs of acute lower respiratory infection with signs of pneumonia or bronchitis: fever and \u002F or cough and \u002F or difficulty breathing in the absence of acute respiratory failure (PaO2\\> 60 mmHg) with Plus or less :\n\n  * Chills\n  * Asthenia, fatigability\n  * Headache\n  * Arthromas myalgia\n  * Dry throat\n  * Rhinorrhea\n  * An anosmia\n  * chest pain\n  * Diarrhea\n  * Nausea and vomiting\n\n    * Absence of rhythm disturbance (Qt interval \\\u003C500ms)\n    * Patients hospitalized in the medical service\n    * 18 years old \\\u003CAge \\\u003C80 years old\n    * Having given written consent for their participation in the study\n\nExclusion Criteria:\n\n* Allergy to macrolides, local anesthetics such as lidocaine or amide type and betalactamines\n* Take hydroxychloquine in the previous month\n* Severe \u002F severe liver failure\n* Kidney failure (GFR \\\u003C30 ml \u002F min \u002F 1.73 m2)\n* Ongoing treatments with colchicine, ergot, rye, pimozide, mizolastine, simvastatin, lomitapide, alfuzosin, dapoxetine, avanafil, ivabradine, eplerenone, dronedarone, quetiapine, ticagrelor, cisapride, astemizole, terfenadine, ranolazine, domperidone.\n* Complete branch block\n* Hypovolemia\n* Retinopathy including vitreous involvement\n* Psoriasis\n* Pregnant or breastfeeding woman\n* hypersensitivity to chloroquine or hydroxychloroquine or to any of the other ingredients of this medication","ALL","18 Years","80 Years",{"count":81,"type":82},0,"ACTUAL","INTERVENTIONAL",[85],"PHASE3","Evaluation of the efficacy and safety of Treatments for Patients Hospitalized for COVID-19 Infection without signs of acute respiratory failure, in Tunisia Multicentric Randomized Comparative Study",[88,89],"COVID 19","Patients Hospitalized","WITHDRAWN","\\- Interest in the use of HCQ is controversial.","2020-08-26",{"date":94,"type":82},"2020-08-27",{"date":96,"type":97},"2020-05-15","ESTIMATED",{"date":99,"type":97},"2020-07-15",{"name":5,"class":6},1]